image
Healthcare - Biotechnology - NASDAQ - US
$ 1.66
0.606 %
$ 62.4 M
Market Cap
-0.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BMEA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.66 USD, Biomea Fusion, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BMEA stock under the base case scenario is HIDDEN Compared to the current market price of 1.66 USD, Biomea Fusion, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BMEA stock under the best case scenario is HIDDEN Compared to the current market price of 1.66 USD, Biomea Fusion, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BMEA

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-144 M OPERATING INCOME
-14.22%
-138 M NET INCOME
-18.06%
-120 M OPERATING CASH FLOW
-24.12%
-362 K INVESTING CASH FLOW
83.69%
1.67 M FINANCING CASH FLOW
-98.98%
0 REVENUE
0.00%
-29.7 M OPERATING INCOME
1.20%
-29.3 M NET INCOME
0.14%
-25.7 M OPERATING CASH FLOW
14.45%
0 INVESTING CASH FLOW
100.00%
3.25 M FINANCING CASH FLOW
687.41%
Balance Sheet Biomea Fusion, Inc.
image
Current Assets 68.3 M
Cash & Short-Term Investments 58.3 M
Receivables 0
Other Current Assets 10.1 M
Non-Current Assets 11.6 M
Long-Term Investments 0
PP&E 10.6 M
Other Non-Current Assets 988 K
72.91 %12.58 %13.28 %Total Assets$79.9m
Current Liabilities 21.7 M
Accounts Payable 12.9 M
Short-Term Debt 2.08 M
Other Current Liabilities 6.66 M
Non-Current Liabilities 6.69 M
Long-Term Debt 0
Other Non-Current Liabilities 6.69 M
45.59 %7.33 %23.49 %23.59 %Total Liabilities$28.4m
EFFICIENCY
Earnings Waterfall Biomea Fusion, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 144 M
Operating Income -144 M
Other Expenses -5.64 M
Net Income -138 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)000(144m)(144m)6m(138m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-268.41% ROE
-268.41%
-173.17% ROA
-173.17%
-238.75% ROIC
-238.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biomea Fusion, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)202020202021202120222022202320232024202420252025
Net Income -138 M
Depreciation & Amortization 0
Capital Expenditures -362 K
Stock-Based Compensation 19.1 M
Change in Working Capital -5.15 M
Others -562 K
Free Cash Flow -120 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biomea Fusion, Inc.
image
Wall Street analysts predict an average 1-year price target for BMEA of $18 , with forecasts ranging from a low of $10 to a high of $40 .
BMEA Lowest Price Target Wall Street Target
10 USD 502.41%
BMEA Average Price Target Wall Street Target
18 USD 984.34%
BMEA Highest Price Target Wall Street Target
40 USD 2309.64%
Price
Max Price Target
Min Price Target
Average Price Target
40403535303025252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Biomea Fusion, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
101 K USD 1
9-12 MONTHS
7. News
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for icovamenib, the company's investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association (ADA) June 20–23, 2025 in Chicago. globenewswire.com - 1 week ago
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company's investigational, next-generation oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). globenewswire.com - 2 weeks ago
Biomea Fusion Shares Fall After Pricing Underwritten Public Offering Shares of Biomea Fusion sank after the company disclosed the pricing of its previously announced underwritten public offering. marketwatch.com - 2 weeks ago
Biomea Fusion Announces Pricing of Public Offering of Securities REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant. globenewswire.com - 2 weeks ago
Stocks to Watch: Biomea Fusion, Bitdeer Technologies Biomea Fusion commenced an underwritten public offering of shares. The stock sank 27% to $2.13 in postmarket trading Tuesday. marketwatch.com - 2 weeks ago
Biomea Fusion Announces Proposed Public Offering of Securities REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). globenewswire.com - 2 weeks ago
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib globenewswire.com - 3 weeks ago
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute leukemia (AL) were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking place June 12–15 in Milan, Italy. globenewswire.com - 1 month ago
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy Biomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 2 months ago
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 3 months ago
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the “Plan”). globenewswire.com - 3 months ago
8. Profile Summary

Biomea Fusion, Inc. BMEA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 62.4 M
Dividend Yield 0.00%
Description Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Contact 900 Middlefield Road, Redwood City, CA, 94063 https://biomeafusion.com
IPO Date April 16, 2021
Employees 79
Officers Dr. Stephan Morris M.D. Chief Development Officer Mr. Ravi Upasani Ph.D. Executive Vice President of Intellectual Property Dr. Juan Pablo Frias M.D. Chief Medical Officer Ms. Naomi Cretcher Chief People Officer Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Chemistry Caroline Perez- Dupont J.D. Senior Vice President of Contracts Dr. Michael J. M. Hitchcock Ph.D. Interim Chief Executive Officer & Director Mr. Heow Tan Chief Technology & Quality Officer Mr. Ramses M. Erdtmann Co-Founder, President, Chief Operating Officer & Director